Venezuela devalues its Bolivar; CPG firms adjust outlook
This article was originally published in The Rose Sheet
Executive Summary
U.S. companies with business in Latin America, where growth has continued despite the global recession, are likely to see reduced earnings in Venezuela as the value of the bolivar drops from approximately 2.15 to 2.6 per dollar for essential goods and 4.3 for non-essentials, in accordance with President Hugo Chavez's devaluation of the country's currency. Colgate-Palmolive expects its products to fall into the non-essential category, according to Jan. 11 release. The devaluation won't affect the firm's 2009 results or competitive position, Colgate says. In the first quarter of fiscal 2010, the firm anticipates recording a one-time gain of $60 mil. ($0.12 per share) and ongoing quarterly charges of $0.04 to $0.06 per share related to the devaluation. The Venezuelan market reportedly represents about 9 percent of Colgate's profits. Procter & Gamble, Avon Products and Burt's Bees owner Clorox Co. are also expected to be affected by the devaluation
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.